MedTrace Logo

Pattern of Use of Bevacizumab or Cetuximab + FOLFIRI Regimen as First-line Treatment in Metastatic Colorectal Cancer

NCT03286738 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 1800

Last updated 2021-04-22

No results posted yet for this study

Summary

* Registry
* Multicenter, prospective observational study
* Observe adverse events and efficacy in recruited patients for 3 years under real world settings.

Conditions

Interventions

DRUG

FOLFIRI, target agent

* Irinotecan (Camtop Injection®, CJ HealthCare Corp.), Leucovorin, 5-Fluorouracil and Bevacizumab * Irinotecan (Camtop Injection®, CJ HealthCare Corp.), Leucovorin, 5-Fluorouracil and Cetuximab

Sponsors & Collaborators

  • Joong Bae Ahn

    lead OTHER

Principal Investigators

  • Joong Bae Ahn · Severance Hospital, YUHS

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-11-30
Primary Completion
2021-12-31
Completion
2021-12-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03286738 on ClinicalTrials.gov